genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Caribou Biosciences
Artificial Intelligence
StockWatch: Nvidia’s $3T Market Cap, Tempus’ $400M IPO Reflect AI Allure
A-Lists
Top 10 Publicly Owned Gene Editing Therapy Companies
GEN Edge
StockWatch: For Genome Editing, Inflection Points Crowd the Calendar
GEN Edge
StockWatch: Caribou Shares Surge on $25M Pfizer Investment
Cancer
Force of Nature: Caribou Biosciences Hits Clinical Runway with CRISPR-based Cancer Therapeutics
Genome Editing
CRISPR’s Second Decade: Jennifer Doudna Looks Forward and Back
Genome Editing
IPO Raises $304M for Caribou, Developer of Gene-Edited Cell Therapies
Cancer
Caribou Rides RNA Wave with $115M Series C Financing
Genome Editing
Long Reads and CRISPR Couple as Oxford Nanopore and Caribou Strike Deal
News
Insights
Scroll Up
Scroll Up
